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Abstract
Background
The United States Preventive Services Task Force supports individualised decision-making
for prostate-specific antigen (PSA)-based screening in men aged 55–69. Knowing how the
potential benefits and harms of screening vary by an individual’s risk of developing prostate
cancer could inform decision-making about screening at both an individual and population
level. This modelling study examined the benefit–harm tradeoffs and the cost-effectiveness
of a risk-tailored screening programme compared to age-based and no screening.
Methods and findings
A life-table model, projecting age-specific prostate cancer incidence and mortality, was
developed of a hypothetical cohort of 4.48 million men in England aged 55 to 69 years with
follow-up to age 90. Risk thresholds were based on age and polygenic profile. We compared
no screening, age-based screening (quadrennial PSA testing from 55 to 69), and risk-tai-
lored screening (men aged 55 to 69 years with a 10-year absolute risk greater than a thresh-
old receive quadrennial PSA testing from the age they reach the risk threshold). The
analysis was undertaken from the health service perspective, including direct costs borne
by the health system for risk assessment, screening, diagnosis, and treatment. We used
probabilistic sensitivity analyses to account for parameter uncertainty and discounted future
costs and benefits at 3.5% per year. Our analysis should be considered cautiously in light of
limitations related to our model’s cohort-based structure and the uncertainty of input param-
eters in mathematical models. Compared to no screening over 35 years follow-up, age-
based screening prevented the most deaths from prostate cancer (39,272, 95% uncertainty
interval [UI]: 16,792–59,685) at the expense of 94,831 (95% UI: 84,827–105,630) overdiag-
nosed cancers. Age-based screening was the least cost-effective strategy studied. The
greatest number of quality-adjusted life-years (QALYs) was generated by risk-based
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screening at a 10-year absolute risk threshold of 4%. At this threshold, risk-based screening
led to one-third fewer overdiagnosed cancers (64,384, 95% UI: 57,382–72,050) but averted
6.3% fewer (9,695, 95% UI: 2,853–15,851) deaths from prostate cancer by comparison with
age-based screening. Relative to no screening, risk-based screening at a 4% 10-year abso-
lute risk threshold was cost-effective in 48.4% and 57.4% of the simulations at willingness-
to-pay thresholds of GBP£20,000 (US$26,000) and £30,000 ($39,386) per QALY, respec-
tively. The cost-effectiveness of risk-tailored screening improved as the threshold rose.
Conclusions
Based on the results of this modelling study, offering screening to men at higher risk could
potentially reduce overdiagnosis and improve the benefit–harm tradeoff and the cost-effec-
tiveness of a prostate cancer screening program. The optimal threshold will depend on soci-
etal judgements of the appropriate balance of benefits–harms and cost-effectiveness.
Author summary
Why was this study done?
• Prostate cancer screening using prostate-specific antigen has been shown to lead to a
reduction in prostate-cancer–specific mortality at the expense of overdiagnosis and
overtreatment.
• Genome-wide association studies have identified more than 160 common genetic vari-
ants that, when combined together as a polygenic risk score, might be used to develop a
tailored screening programme for prostate cancer.
• The proportion of men overdiagnosed has been shown to vary by polygenic risk; there-
fore, a risk-tailored screening based on age and polygenic risk profile may improve the
balance of benefits and harms of a screening programme for prostate cancer.
What did the researchers do and find?
• We developed a mathematical model that simulated hypothetical cohorts of 4.48 million
men aged 55 to 69 in England.
• Using this model, we analysed the balance of benefits and harms in terms of prostate-
cancer–specific mortality reduction against overdiagnosis, as well as the cost-effective-
ness, of the introduction of a risk-tailored screening programme for prostate cancer
based on age and polygenic risk.
• We compared risk-tailored screening to age-based screening and no screening.
What do these findings mean?
• Based on this model, we show that a polygenic risk-tailored screening programme
might reduce overdiagnosis, maintain the mortality benefits of age-based screening, and
improve the cost-effectiveness of a screening programme for prostate cancer.
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• The ideal threshold for risk-tailored screening will depend on societal judgement of the
tradeoff between the benefits and harms of screening.
• Future prospective evaluations are needed to verify these findings.
Introduction
Screening with a prostate-specific antigen (PSA) test could reduce death from prostate cancer
in some men but at the cost of substantial numbers overdiagnosed, as well as false positive
results [1]. Overdiagnosed cancers are the screen-detected cancers that would not otherwise
have come to light during an individual’s lifetime [2], whose diagnosis and related treatment
can lead to avoidable physical and psychological harms whilst also incurring an economic cost
[3]. The updated 2018 guidelines of the US Preventive Services Taskforce recommend consid-
eration of screening for certain at risk men between the ages of 55 and 69 [1]. Understanding
the variation in the potential benefits and harms of screening by an individual’s risk of devel-
oping prostate cancer could inform decision-making about screening at both the individual
and population level.
Genome-wide association studies have identified common susceptibility loci that together
explain approximately 37% of the familial relative risk of prostate cancer [4]. Individually,
these loci have little clinical significance [5]. However, together they define a risk distribution
with a variance of 0.68 and area under the curve (AUC) of 0.72 that can be used to stratify indi-
viduals into groups at higher and lower risk of developing prostate cancer [2,6], enabling tai-
lored screening by risk group. Individuals in the first and 99th percentiles of the polygenic risk
distribution have relative risks of developing prostate cancer of 0.09 and 5.52, respectively,
compared to the population mean. Almost 49% of prostate cancers occur in those men in the
highest 20% of the polygenic risk distribution, and only 7% occur amongst those in the lowest
20% of the risk distribution (Fig C in S1 Appendix). Avoiding screening of those at lower risk
may consequently reduce the harms of screening without a commensurate loss of benefit. The
proportion of prostate cancers overdiagnosed varies inversely with polygenic risk, with almost
50% lower overdiagnosis in men in the highest quartile compared with the lowest quartile of
polygenic risk [2]. This approach to screening would require genotyping of all men for the pur-
pose of risk assessment. However, the additional costs of population-wide genotyping may be
offset by lower levels of overtreatment.
The aims of this study were to assess the balance of benefit and harms, as well as the cost-
effectiveness, of the introduction of a polygenic risk-tailored screening programme for prostate
cancer.
Methods
Model structure
We developed a life-table model (Fig A in S1 Appendix) to simulate cohorts of men under 3
scenarios: no screening, age-based screening with PSA, and risk-tailored screening (hence-
forth, precision screening). Our life table is a cohort-based Markov model that estimates the
age-specific incidence of prostate cancer, deaths from prostate cancer, and deaths from other
causes. Each hypothetical cohort consisted of 4.48 million men aged 55 to 69, representing the
Precision screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
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mean population of men of this age in England in 2013–2016 [7]. All cohorts were assumed to
be prostate-cancer–free on entering the model and were followed up to the age of 90.
Age-based screening involved PSA testing every 4 years between the ages of 55 and 69,
reflecting the screening interval used in the core analyses of the European Randomized Study
of Screening for Prostate Cancer [8]. In the precision screening cohort, we estimated the
10-year absolute risk of developing prostate cancer based on age and polygenic profile. From
the age of 55 to 69, this cohort of men started quadrennial PSA screening at the age at which
they reached a specified risk threshold, which was varied between a 2% and 10% 10-year abso-
lute risk of developing prostate cancer. We set a PSA cutoff of 3.0 ng/mL for suspected prostate
cancer requiring further assessment for both the age-based and precision screening cohorts.
Precision screening
The distribution of polygenic risk on a relative risk scale in the population is log-normal,
assuming a log-additive interaction between loci [6]. The variance of the polygenic risk distri-
bution was calculated as 0.68, based on known prostate cancer susceptibility variants (see S1
Appendix for further details) [6,9].
We calculated the log relative risk of developing prostate cancer for each risk threshold
respective to the background 10-year absolute risk of developing prostate cancer in the absence
of screening. By applying the log relative risk of developing prostate cancer to the polygenic
risk distribution, we then determined the proportion above the risk threshold and the propor-
tion of all cases of prostate cancer accounted for amongst those above the threshold. From
this, we derived the relative risk of developing prostate cancer in those who were screened or
not screened.
Model parameters
Model parameters are shown in Table 1. We used Office for National Statistics data and Dev-
Can software to calculate the age-specific incidence of prostate cancer, mortality from prostate
cancer, and mortality from other causes, accounting for competing risks (Table B in S1 Appen-
dix) [10]. The incidence of prostate cancer in the nonscreened cohorts was adjusted by 10% to
reflect the estimated proportion of cancers that are diagnosed as a result of opportunistic
screening in England (see S1 Appendix for further details). Costs were estimated from the per-
spective of the National Health Service (NHS) in 2016 prices using Unit Costs of Health and
Social Care and NHS Reference Costs, which have been previously validated for use in costing
prostate cancer care (Table 1 and Table A in S1 Appendix) [11–13]. We determined the pro-
portion receiving different treatments by stage at diagnosis from the National Cancer Registra-
tion and Analysis Service, the National Prostate Cancer Audit, and National Institute for
Health and Care Excellence (NICE) guidelines [14–16]. The cost of polygenic risk stratification
was based on an empirical estimate.
We developed utility weights for those with prostate cancer based on treatment modality
(see S1 Appendix for further details). We estimated the number of overdiagnoses by multiply-
ing the number of screen-detected cases by the age-specific proportion estimated to be at risk
of overdiagnosis [17].
Model outputs
We calculated costs, the number of quality-adjusted life-years (QALYs), life-years, prostate
cancer cases, overdiagnoses, deaths from prostate cancer, and the number of overdiagnoses
per prostate cancer death averted. Both costs and benefits were discounted at 3.5% per annum,
as per NICE guidelines [28].
Precision screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
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Table 1. Model parameters.
Parameter Value (95% CI)a Distribution Used in
Probabilistic Analyses (α,
β)b
Description Source
Life table
RR of prostate-cancer–specific
mortality with screening
0.79 (0.69 to
0.91)
Log-normal [SE: 0.06] The relative reduction in mortality seen with screening with PSA in the
ERSPC.
[8]
RR of incidence of prostate
cancer with screening
1.23 (1.03 to
1.48)
Log-normal [SE: 0.18] Relative increase in the incidence of prostate cancer in the presence of
screening with PSA, derived from a meta-analysis of randomised
controlled trials of PSA screening.
[18]
Proportion overdiagnosed −0.62
+ age × 0.014
Beta [SE: 0.001] Derived from linear regression of estimates for the risk of overdiagnosis
in 5-year age groups.
[2]
RR of advanced cancer at
diagnosis if screened
0.85 (0.72 to
0.99)
Log-normal [SE: 0.07] Relative decrease in the proportion of cancers that are considered
advanced (stages III or IV) if screen-detected, derived from a meta-
analysis of randomised controlled trials of PSA screening.
[18]
Utility values
General population utility 0.8639 (0.852 to
0.875)
0.83 + Gamma (4, 0.06) ×
0.167
A yearly utility decline of 0.0048 (0.004 to 0.006) was estimated from
linear regression of the mean health state values in 5-year intervals from
45 to 90 against age.
[19]
Relative reduction in utility for
those with prostate cancer
0.93, range: [0.88
to 1.0]
0.88 + Gamma (5, 0.05) ×
0.2
Average over 10 years. Sampled from a right-skewed distribution in
probabilistic analysis.
[20]
Costs (GBP£ in 2016 prices)c,d
PSA testing 11 (7 to 15) Gamma (33.9, 0.3) [11,12]
Polygenic risk stratification 25 (17 to 33) Gamma (33.9, 0.7) Empirical estimate calculated from the laboratory costs of genotyping a
similar number of SNPs.
Biopsy 388 (260 to 516) Gamma (33.9, 11.5) [11,21,22]
Declined biopsy, but had a
PSA� 3.0 ng/ml
105 (70 to 140) Gamma (33.9, 3.1) Individuals who declined biopsy but had a PSA� 3.0 ng/ml were
assumed to have one urological appointment.e
[11]
Staging of diagnosed cancer 770 (516 to
1,024)
Gamma (33.9, 22.7) Cost of staging with MRI and an isotope bone scan. [11,21,22]
Active surveillance 4,341 (2,908 to
5,774)
Gamma (33.9, 128.1) Average over 10 years, assuming that 55% will go on to have radical
therapy during this time period.
[11,23,24]
Radical prostatectomy 8,173 (5,476 to
10,870)
Gamma (33.9, 241.2) Incorporating the costs of complications and follow-up over 5 years. [11,21,22]
Radical radiotherapy 5,385 (3,608 to
7,162)
Gamma (33.9, 158.9) Incorporating the costs of complications and follow-up over 5 years. [11,21,22]
Brachytherapy 1,527 (1,023 to
2,031)
Gamma (33.9, 45.1) [11,21,22]
Chemotherapy 7,426 (4,975 to
9,877)
Gamma (33.9, 219.2) [11,21,25]
Androgen deprivation therapy 559 (375 to 744) Gamma (33.9,16.5) Derived from the NICE costing statement of its prostate cancer, inflated
to 2015–2016 prices, with the addition of 1 urological appointment as
follow-up.
[16]
Palliation and death from
prostate cancer
6,837 (535 to
20,257f)
Gamma (1.8, 3854.9) Inflated from 2013–2014 estimated costs to the healthcare system in the
last 12 months of life.
[26]
a95% CI unless otherwise stated.
bα and β parameters shown unless otherwise stated.
cIn sensitivity analyses, it was assumed that 95% of the costs are likely to vary no more than approximately one-third from the calculated baseline value [27].
dAll costs are in 2016 GBP£.
eExcept in sensitivity analysis, all men eligible for biopsy were assumed to have one.
f95% credible interval—see Table A in S1 Appendix for further details. Abbreviations: CI, confidence interval; ERSPC, European Randomized Study of Screening for
Prostate Cancer; NICE, National Institute for Health and Care Excellence; PSA, prostate-specific antigen; RR, relative risk; SE, standard error; SNP, single nucleotide
polymorphism.
https://doi.org/10.1371/journal.pmed.1002998.t001
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We calculated incremental cost-effectiveness ratios (ICERs) by dividing the difference in
mean costs between the compared scenarios by the difference in mean QALYs, derived from
10,000 probabilistic simulations [29]. The net monetary benefit (NMB) was calculated by sub-
tracting the costs from the product of the QALYs and the willingness-to-pay threshold. We
ranked the cost-effectiveness of each screening strategy using different risk thresholds by
NMB, using willingness-to-pay thresholds of £20,000 ($26,000) and £30,000 ($39,000) per
QALY gained because these reflect the range of thresholds used by NICE in the consideration
of the cost-effectiveness of an intervention [28].
Probabilistic and deterministic sensitivity analyses
To account for uncertainty in the parameters, we ran 10,000 simulations for each screening
scenario; the distributions used for each input varied are shown in Table 1. The results pre-
sented are probabilistic unless otherwise stated. In sensitivity analyses, we evaluated precision
screening starting at the age of 45, 50, and 60; the impact of different levels of screening uptake
and adherence; overdiagnosis when adjusted for polygenic risk; and the cost of polygenic test-
ing. We used Python v3.6.5 for all analyses; the code is available at https://github.com/callta/
precision_screening_pca. The CHEERS checklist [30] was used in the preparation of this
manuscript.
Results
Risk of developing prostate cancer
Our analyses show that the background 10-year absolute risk of developing prostate cancer in
the absence of screening rose from 2.6% to 7.1% between the ages of 55 and 69 (Fig B in S1
Appendix). Just under half of men aged 55 (49.1%) had a 10-year absolute risk of developing
prostate cancer of�2% based on age and polygenic risk profile, increasing to 90.6% of men
aged 69. The proportion of men by age at or above each 10-year absolute risk threshold is
shown in Fig E in S1 Appendix.
Benefits and harms of screening
In a hypothetical cohort of 4.48 million men, age-based screening led to 39,272 fewer deaths
from prostate cancer and to 94,831 overdiagnoses, representing 2.4 overdiagnoses per prostate
cancer death averted, as well as 764,446 additional biopsies over 35 years follow-up, by com-
parison with no screening. The tradeoff between the benefits and harms of precision screening
varied by risk threshold (Fig 1, Table 2, Table C in S1 Appendix). In the precision screening
cohort, at a 2% 10-year absolute risk threshold, 36,534 deaths from prostate cancer were pre-
vented at the expense of 84,681 overdiagnoses by comparison with no screening. As the risk
threshold was raised to 10%, 14,507 deaths were prevented and 26,791 overdiagnosed by com-
parison with no screening. This represented a drop in the ratio of overdiagnosed cases to pros-
tate cancer deaths prevented from 2.3 to 1.8 at risk thresholds of 2% and 10%, respectively (Fig
F in S1 Appendix), and there was a reduction in the number of additional biopsies performed
from 652,177 to 150,635 (Table C in S1 Appendix).
Cost-effectiveness
Age-based screening led to an additional 16,416 QALYs by comparison with no screening, at a
cost of £574 million ($746 million) over 35 years, such that the ICER was £34,952 ($45,437)
per QALY gained. In 40.7% of simulations, the ICER of age-based compared with no screening
was�£20,000 ($26,000) per QALY gained.
Precision screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
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In the precision screening model, below a 4.5% 10-year absolute risk threshold, there was a
plateau in the QALYs gained by comparison with no screening that subsequently began to fall
as the risk threshold was raised, whilst the costs of precision screening continued to drop as
the risk threshold increased (Fig 2). At all 10-year absolute risk thresholds below 10%, preci-
sion screening led to a greater number of incremental QALYs gained than age-based screening
whilst incurring fewer additional costs at all risk thresholds above 2% (Fig 2).
At a 2% 10-year absolute risk threshold, the ICER was £30,297 ($39,386) per QALY gained.
This declined as the risk threshold increased, reaching a plateau at a threshold of approxi-
mately 7%, at which point the ICER was £16,755 ($21,781) per QALY gained. Precision screen-
ing was cost-effective at a willingness-to-pay threshold of £20,000 ($26,000) per QALY gained
compared to no screening at all 10-year absolute risk thresholds above 4.5%. At a risk thresh-
old of 5%, precision screening had a 51.5% probability of being cost-effective and an ICER of
£19,598 ($25,478), rising to a 62.5% probability of being cost-effective and an ICER of £14,862
($19,320) at a threshold of 10%.
NMB of screening strategies
Comparing all precision and age-based strategies with no screening, the highest NMB at will-
ingness-to-pay thresholds of £20,000 ($26,000) and £30,000 ($39,000) per QALY was seen with
precision screening at a 10% and 8% 10-year absolute risk threshold, respectively. Screening
strategies by NMB are presented in Fig H in S1 Appendix, whilst the cost-effectiveness accept-
ability planes, curves, and frontier are shown in Figs I–J in S1 Appendix. Age-based screening
had a lower NMB than all precision screening strategies.
Fig 1. Overdiagnosed cases and prostate cancer deaths prevented with precision screening as compared to age-based screening. Results based on 10,000
simulations.
https://doi.org/10.1371/journal.pmed.1002998.g001
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Sensitivity analyses
The results of sensitivity analyses are available in S1 Appendix.
Discussion
This modelling analysis has shown that precision screening based on age and polygenic risk
could reduce overdiagnosis whilst preserving most of the mortality benefits of age-based
screening for prostate cancer. At all risk thresholds studied, precision screening had a higher
NMB, lower ICER, and fewer overdiagnosed prostate cancers than age-based screening. The
cost-effectiveness of screening increases as the risk threshold rises, plateauing at a risk thresh-
old of approximately 7%. However, the greatest QALY gains are at a 10-year absolute risk
threshold of 4%. A precision screening programme using a 4% risk threshold would reduce
overdiagnosis by one-third, yield more QALYs, and cost less whilst maintaining the benefits of
screening. The ideal strategy will depend on both a society’s willingness to pay for each QALY
gained as well as the tradeoff between benefits and harms considered acceptable both at an
individual and population level [31].
Table 2. Outcomes of age-based and precision screening compared with no screening.
Screening
Strategy
Prostate
Cancer
Cases (n)
Difference
with No
Screening
Overdiagnosed
Cases (n)
Deaths
from
Prostate
Cancer (n)
Difference
with No
Screening
QALYs
(n)
Difference
with No
Screening
Costs (£
Millions)
Difference
with No
Screening (£
Millions)
ICER
(£/QALY
Gained)
Cumulative
Percentage
Screeneda (%)
No
screening
537,870 N/A 192,623 46,682,945 2,975 0
Age-based
screening
644,047 106,177 94,831 153,351 −39,272 46,699,360 16,416 3,549 574 34,952 100
Precision
screening
(10-year
AR)
2.0% 622,733 84,863 84,681 156,089 −36,534 46,702,653 19,709 3,572 597 30,297 75.4
2.5% 614,230 76,360 79,620 157,723 −34,900 46,703,346 20,401 3,537 562 27,542 66.7
3.0% 606,014 68,144 74,419 159,482 −33,141 46,703,788 20,844 3,503 527 25,290 58.9
3.5% 598,318 60,448 69,298 161,275 −31,348 46,704,012 21,067 3,469 494 23,446 51.9
4.0% 591,244 53,375 64,384 163,045 −29,578 46,704,054 21,109 3,438 463 21,924 45.8
4.5% 584,818 46,949 59,743 164,759 −27,864 46,703,950 21,006 3,409 434 20,659 40.5
5.0% 579,026 41,156 55,406 166,397 −26,226 46,703,733 20,788 3,383 407 19,598 35.9
5.5% 573,830 35,960 51,379 167,947 −24,676 46,703,427 20,482 3,358 383 18,704 31.9
6.0% 569,186 31,316 47,656 169,407 −23,216 46,703,054 20,109 3,336 361 17,947 28.4
6.5% 565,045 27,175 44,224 170,775 −21,848 46,702,631 19,686 3,316 341 17,303 25.4
7.0% 561,358 23,488 41,065 172,055 −20,568 46,702,172 19,227 3,298 322 16,755 22.7
7.5% 558,079 20,209 38,160 173,250 −19,373 46,701,687 18,743 3,281 305 16,289 20.4
8.0% 555,165 17,295 35,490 174,364 −18,258 46,701,187 18,242 3,265 290 15,894 18.4
8.5% 552,577 14,707 33,036 175,403 −17,220 46,700,677 17,732 3,251 276 15,560 16.6
9.0% 550,279 12,410 30,779 176,371 −16,251 46,700,163 17,218 3,238 263 15,281 15.0
9.5% 548,241 10,371 28,703 177,274 −15,349 46,699,649 16,704 3,227 251 15,050 13.6
10.0% 546,432 8,562 26,791 178,116 −14,507 46,699,140 16,195 3,216 241 14,862 12.3
Outcomes shown in hypothetical cohorts of 4.8 million men aged 55 to 69 in England, followed up to age 90. Abbreviations: AR, absolute risk; ICER, incremental cost-
effectiveness ratio; N/A, not applicable; QALY, quality-adjusted life-year.
aTotal cumulative proportion eligible for screening by the aged 69. See Fig E in S1 Appendix for an indication of the proportions eligible for precision screening as they
age by different risk thresholds. Each ICER represents that specific screening strategy compared with no screening.
https://doi.org/10.1371/journal.pmed.1002998.t002
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A plateau is also seen in the cost-effectiveness as the risk threshold for precision screening
rises (Table 2, Fig 2). This reflects the fact that fewer deaths are being prevented relative to the
increased number of prostate cancer cases, and therefore the greater number of years lived
with prostate cancer, as men at higher risk are screened. The incremental QALYs gained with
precision screening begin to drop at a 10-year risk threshold above 4%. However, the ICER of
precision screening does not begin to plateau until the 10-year absolute risk threshold is raised
to 7%. Together, this suggests that a strategy of precision screening at a 10-year absolute risk
threshold of between 4% and 7% may provide the most appropriate balance of harms and ben-
efits, considering prostate cancer deaths prevented, cases overdiagnosed, and QALYs gained
for the additional costs of screening.
Screening men at a higher risk of prostate cancer lowers the proportion of overdiagnosed
cases, the number of additional biopsies performed, and the ratio of overdiagnosed cases to
prostate cancer deaths averted. As the risk threshold rose, a smaller proportion of men became
eligible for screening. Overdiagnosis dropped as the risk threshold increased. With fewer men
screened, there were fewer prostate cancer deaths averted compared to age-based screening.
However, the extent of the drop in overdiagnosis was greater than the extent of prostate cancer
deaths not prevented, leading to an improvement in the benefit–harm profile as the risk
threshold rose (Fig G in S1 Appendix).
In the UK, NICE considers interventions with an ICER of�£20,000 per QALY gained as
cost-effective, a threshold that was reached with all precision screening strategies above a 5%
10-year absolute risk threshold [28]. A precision screening strategy using a 5% 10-year absolute
risk reflects the average risk of developing prostate cancer in men aged 61 in England. A pro-
gramme employing this strategy would screen 1 in 10 men (11.4%) at the age of 55, rising to
just over half (50.5%) by the age of 69. This strategy would reduce overdiagnosis by a 41.6%,
yield more QALYs, and cost less, at the expense of 8.5% fewer prostate cancer deaths averted
by comparison with age-based screening.
Precision screening for prostate cancer would involve an evolution in screening services,
with logistical and ethical implications. Risk tailoring implies that different individuals are
invited to screening at different ages, with potential knock-on effects on screening delivery
Fig 2. Incremental cost and QALYs of precision and age-based screening compared with no screening. Results based on 10,000 simulations. The solid lines describe
the incremental costs incurred and QALYs gained of precision screening versus no screening, whilst the dashed lines represent the incremental costs and QALYs of age-
based versus no screening. QALY, quality-adjusted life-year.
https://doi.org/10.1371/journal.pmed.1002998.g002
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[32]. In addition, although the disclosure of genetic material to insurance companies is covered
under a moratorium in England [33], the broader impact of risk-tailored screening using
genetic material on individuals and society requires further research. Finally, the introduction
of screening programmes could risk widening health inequalities between both socioeconomic
classes and ethnic groups, which can occur as a result of varied uptake amongst different socio-
economic strata and ethnicities of screening [34,35]. Research to mitigate this occurrence
should be considered alongside prospective studies of polygenic risk-based screening.
In a precision screening programme, in addition to altering the screening start age, the fre-
quency of screening could be varied according to risk. For example, men at higher risk may
receive more frequent screening and men at lower risk receive less frequent or no screening.
Intensified screening could improve the benefit–harm tradeoffs if the sojourn time—the time
it takes to progress from preclinical screen-detectable cancer to clinically detectable cancer—
varies with risk level [36]. In the absence of these data in the context of polygenic risk, the
impact of varying screening intervals was not estimated.
There have been no comparable studies estimating the impact of polygenic risk-tailored
screening in prostate cancer. However, the conclusions reached from our precision and age-
based screening models compare favourably with a microsimulation model from the US [37],
attesting to the underlying robustness of our model in spite of the differences in model design
and assumptions. Using a microsimulation model and a selective treatment strategy involving
initial conservative management for those with localised cancer (Gleason score <7 and stage
T2a), Roth and colleagues state that quadrennial age-based screening between the ages of 55
and 69 with a PSA cutoff of 3 ng/ml would lead to 30 additional QALYs per 10,000 men
screened (37 in this analysis) [37].
Limitations
Follow-up of individuals ended at the age of 90, reflecting the increasing uncertainty in esti-
mates regarding the incidence and mortality from prostate cancer beyond this age. A life-table
approach using aggregate data has been used because of uncertainty in how the natural history
of prostate cancer varies by risk. Recent data suggest that there is limited variation in health-
related quality of life between stages of prostate cancer, with diminishing utility at higher stages
of disease [38]. Because screening leads to a greater proportion of cases detected at early stages,
the QALYs recorded in screened cohorts in our model may be underestimated. However, our
approach produces similar results to microsimulation models taking into account natural his-
tory for age-based screening [37]. Simplifying the model structure in this way minimises the
number of underlying assumptions, whilst parameter uncertainty is accounted for with proba-
bilistic sensitivity analyses. The estimates of resource use are limited by the absence of data
regarding whether the stage at diagnosis of screen-detected cancers and whether response to
treatment varies by polygenic risk.
Because there are no data on how overdiagnosis varies for each percentile of the risk distri-
bution, we have assumed the proportion overdiagnosed is equivalent to that seen with PSA
screening alone. In sensitivity analyses in which we assume overdiagnosis to vary with poly-
genic risk, the balance of benefits and harms of precision screening is substantially improved,
suggesting that our model underestimates the potential benefits of precision screening (Fig M
in S1 Appendix). We have also assumed that precision screening does not lead to a greater rel-
ative risk reduction in mortality than age-based screening. Polygenic hazard scores have been
shown to be predictive of aggressive cancer, which potentially could disproportionately benefit
from screening [39]. This may lead to a more conservative estimate of the benefit/harm ratio
attributed to precision screening in this model.
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Conclusion
Our analyses show that precision screening based on age and polygenic risk profile could
improve the benefit/harm tradeoff and cost-effectiveness of a screening programme for pros-
tate cancer. Offering screening to men at a 10-year absolute risk threshold between 4% and 7%
could lead to greater QALYs, lower costs, and a 32.1% to 56.7% reduction in overdiagnosis
when compared to age-based screening. These findings require verification by a prospective
randomised evaluation.
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